Cocrystal Pharma, Inc. (COCP) stock
Close on Nov 12, 2026Market cap $19.07MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $19.07M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 18.27
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$9.94M
- EPS, diluted
- -$0.77
- Free cash flow
- -$8.20M
- Book value per share
- $0.08
- Diluted shares
- 14M
Trading
- Previous close
- $1.02
- Open
- $0.99
- Day's range
- $0.99 – $1.04
- Volume
- 22,477
- Average volume (20 days)
- 34,628
- Beta (5 years)
- 1.13
- 52-week range
- $0.76 – $2.03
- RSI (14 days)
- 44.6
- Volatility (1 year)
- 74.7%
- Relative volume
- 0.45×
- WACC
- 10.5%
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | COCP | S&P 500 | Difference | COCP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -6.6% | -2.7% | −3.9 pts | ||
| 3 months | -11.6% | -1.7% | −9.9 pts | ||
| Year to date | +1.1% | +11.9% | −10.8 pts | ||
| 1 year | -10.0% | +12.0% | −22.0 pts | ||
| 3 years | -47.9% | +78.2% | −126.1 pts | -19.5% | +21.2% |
| 5 years | -90.9% | +73.2% | −164.2 pts | -38.1% | +11.6% |
| 10 years | -99.4% | +309.6% | −409.1 pts | -40.4% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cocrystal Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About Cocrystal Pharma
Pharmaceutical Preparations
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that discovers and develops novel antiviral therapeutics targeting serious and chronic viral infections. The company applies a proprietary structure-based drug discovery platform combining computational chemistry, medicinal chemistry, X-ray crystallography, and enzymology to design direct-acting small molecule antivirals. Its research and development programs focus on RNA viruses, specifically developing product candidates for influenza, norovirus, coronaviruses, and hepatitis C.
Company profile, executives and historyCocrystal Pharma stock: common questions
What is Cocrystal Pharma's stock price?
COCP closed at $0.99 on Nov 12, 2026, down 2.94% on the day. Over the past 52 weeks it traded between $0.76 and $2.03.
What is Cocrystal Pharma's market cap?
Cocrystal Pharma was worth $19.07M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is COCP's P/E ratio?
Cocrystal Pharma lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.77), so it has no meaningful P/E ratio.
Does Cocrystal Pharma pay a dividend?
No. Cocrystal Pharma has not paid a cash dividend over the last twelve months.
How has COCP stock performed over the past year?
Including dividends, COCP returned -10.0% over the past year, against +12.0% for the S&P 500.
How many COCP shares are sold short?
0M shares were sold short at the latest FINRA report, 2.37% of the float, or 4.9 days of average trading volume.
Who are Cocrystal Pharma's competitors?
Companies most similar to Cocrystal Pharma by business, industry and size include AVIR, ASMB, DCOY, ENTA, NNVC.
See a number that looks wrong?